Impact of Chronic and Acute Caffeine Intake on the Hematopoietic System
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Caffeine (200 mg).
- Who it may be relevant to
- Registry conditions: Healthy Adults; Hematopoietic System; Caffeine. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
CaffeineHSC - Effect of Chronic Caffeine Consumption and Acute Caffeine Administration on the Hematopoietic System
Overview
This study investigates how caffeine intake affects blood stem and progenitor cells in healthy adults. The trial will compare people who regularly consume caffeine with those who consume very little or none. All participants will receive a single 200 mg caffeine tablet (similar to one cup of coffee) under fasting conditions. Blood samples will be collected before and three hours after caffeine intake. The study will assess whether caffeine influences the mobilization of blood stem and progenitor cells from the bone marrow into the bloodstream. It will also examine the effects of caffeine on the function, gene activity, and metabolism of blood cells.
Interventions
- Other Caffeine (200 mg)
Participants receive a single oral dose of 200 mg caffeine under fasting conditions. Blood samples are collected before and three hours after intake to evaluate effects on hematopoietic stem and progenitor cells, including mobilization, function, gene expression, and metabolism.
Primary outcome measures
- Mobilization of hematopoietic stem and progenitor cells [Time frame: From baseline to three hours after caffeine intake]
- Mobilization of hematopoietic stem and progenitor cells [Time frame: From baseline to three hours after caffeine intake]
Secondary outcome measures (6)
- Functional alterations in CD34+ peripheral blood cells [Time frame: From baseline to three hours after caffeine intake]
- Functional alterations in CD34+ peripheral blood cells [Time frame: From baseline to three hours after caffeine intake]
- Transcriptional changes in CD34+ cells [Time frame: From baseline to three hours after caffeine intake]
- Relative metabolite abundance [Time frame: From baseline to three hours after caffeine intake]
- Change in the numbers of peripheral blood cells [Time frame: From baseline to three hours after caffeine intake]
- Change in the numbers of peripheral blood cells [Time frame: From baseline to three hours after caffeine intake]
Eligibility criteria
Inclusion criteria
- Able to give consent.
- Healthy adults aged ≥ 18 years.
- Regular caffeine consumers (≥1 coffee cup/day or ≥1 energy drink/day) or non-consumers (≤1 cup/month and ≤1 energy drink/month) for at least 6 months.
- Willingness to comply with fasting requirements and study procedures.
Exclusion criteria
- Chronic illnesses or medication use affecting metabolism, including metabolic disorders (e.g., diabetes, thyroid dysfunction, metabolic syndrome).
- Personal history of cancer.
- Personal history of hematological disorders.
- History of radiation therapy.
- Known caffeine hypersensitivity or intolerance.
- Known immunosuppression.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
Switzerland · 2 centers
- ETH GLC — Zurich
- ETH GLC — Zurich
Identifiers
NCT: NCT07193264 · 2025-00914